drugset / Trial / NCT05057715
huCART-meso + VCN-01 in Pancreatic and Ovarian Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a single-center phase 1 study to evaluate the safety and feasibility of huCART-meso cells given in combination with VCN-01 in patients with unresectable or metastatic pancreatic adenocarcinoma and serous epithelial ovarian cancer.
Timeline
- Start
- 2022-03-02
- Primary completion
- 2038-09
- Completion
- 2038-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | huCART-meso | Cell therapy | 5e+07 cells | Intravenous |
| Subject | zabilugene almadenorepvec | Unknown | 3.3e+12 unknown | Intravenous |
| Subject | zabilugene almadenorepvec | Unknown | 1e+13 unknown | Intravenous |